Akari Therapeutics (AKTX) Retained Earnings (2011 - 2026)
Akari Therapeutics recorded quarterly Retained Earnings of -$279.0 million in Q1 2026, down 35577.75% quarter-over-quarter from -$782000.0 in Q4 2025, and down 11.16% year-over-year from -$314.0 million in Q1 2025.
Akari Therapeutics' Retained Earnings history runs 16 years deep, the most recent figure standing at -$279.0 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 11.16% year-over-year to -$279.0 million; the TTM figure through Mar 2026 stood at -$279.0 million (down 11.16% YoY), while the FY2025 annual figure was -$782000.0, up 99.68% from the prior year.
- Retained Earnings came in at -$279.0 million for Q1 2026 at Akari Therapeutics, down from -$782000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$749000.0 in Q2 2024 to a low of -$279.0 million in Q1 2026.
- A 5-year average of -$203.4 million and a median of -$230.2 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings plunged 126628.25% in 2022 and surged 99.68% in 2025, its largest moves.
- Akari Therapeutics' Retained Earnings stood at -$217.5 million in 2022, then fell by 4.6% to -$227.5 million in 2023, then declined by 8.7% to -$247.3 million in 2024, then soared by 99.68% to -$782000.0 in 2025, then sank by 35577.75% to -$279.0 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$279.0 million, -$782000.0, and -$259.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -622,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -279.00 Mn |
| Dec 31, 2025 | -782,000.00 |
| Sep 30, 2025 | -259.25 Mn |
| Jun 30, 2025 | -1.11 Mn |
| Mar 31, 2025 | -773,000.00 |
| Dec 31, 2024 | -738,000.00 |
| Sep 30, 2024 | -926,000.00 |
| Jun 30, 2024 | -240.60 Mn |
| Mar 31, 2024 | -233.03 Mn |
| Dec 31, 2023 | -1.04 Mn |
| Jun 30, 2023 | -220.45 Mn |
| Dec 31, 2022 | -217.45 Mn |
| Jun 30, 2022 | -210.56 Mn |
| Mar 31, 2022 | -204.88 Mn |
| Dec 31, 2021 | -171,590.00 |
| Sep 30, 2021 | -193.92 Mn |
| Jun 30, 2021 | -192.47 Mn |
| Mar 31, 2021 | -188.12 Mn |
| Dec 31, 2020 | -648,065.00 |
| Sep 30, 2020 | -621,298.00 |
| Jun 30, 2020 | -617,622.00 |
| Mar 31, 2020 | -168.94 Mn |
| Dec 31, 2019 | -348,860.00 |
| Sep 30, 2019 | -402,093.00 |
| Jun 30, 2019 | -154.49 Mn |
| Mar 31, 2019 | -148.54 Mn |
| Dec 31, 2018 | -352,426.00 |
| Sep 30, 2018 | -123.29 Mn |
| Jun 30, 2018 | -119.70 Mn |
| Mar 31, 2018 | -111.68 Mn |
| Dec 31, 2017 | -236,246.00 |
| Sep 30, 2017 | -98.22 Mn |
| Jun 30, 2017 | -87.84 Mn |
| Mar 31, 2017 | -87.52 Mn |
| Dec 31, 2016 | -280,097.00 |
| Sep 30, 2016 | -66.65 Mn |
| Jun 30, 2016 | -66.23 Mn |
| Mar 31, 2016 | -36,464.00 |
| Dec 31, 2015 | 156,480.00 |
| Sep 30, 2015 | 197,091.00 |
| Jun 30, 2015 | -34.18 Mn |
| Mar 31, 2015 | -32.51 Mn |
| Dec 31, 2014 | 46,081.00 |
| Dec 31, 2013 | -33,357.00 |
| Dec 31, 2012 | -16.92 Mn |
| Dec 31, 2011 | -12.62 Mn |